Valuation : Vitrolife AB

Market Cap 12.11B 1.25B 1.08B 1.02B 924M 1.73B 119B 1.74B 4.66B 60.76B 4.7B 4.59B 192B P/E 2026 *
24.6x
P/E 2027 * 19.9x
Enterprise Value 12.66B 1.31B 1.13B 1.07B 966M 1.81B 125B 1.82B 4.87B 63.52B 4.91B 4.8B 201B EV / Sales 2026 *
3.66x
EV / Sales 2027 * 3.26x
Free-Float
54.39%
Yield 2026 *
1.24%
Yield 2027 * 1.41%
3 months-13.64%
6 months-13.64%
Current year-36.94%
Current year 9.5
Extreme 9.5
15.3
1 year 9.5
Extreme 9.5
18.55
3 years 9.5
Extreme 9.5
25
5 years 9.5
Extreme 9.5
59.29
10 years 9.5
Extreme 9.5
59.29
Manager TitleAgeSince
Chief Executive Officer 52 2023-07-31
Director of Finance/CFO 55 2025-10-09
Chief Investment Officer 40 -
Director TitleAgeSince
Director/Board Member 63 2013-04-18
Chairman 70 2023-07-31
Chairman 55 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.25B
-1.04%-2.50%+186.69%+384.25% 21.12B
-1.68%-5.19%-38.84%-22.11% 9.62B
+3.33%+9.48%+442.64%+38.20% 8.94B
+1.25%-2.91%-28.54% - 6.88B
-0.14%-0.71%+89.37%+56.40% 6.54B
0.00%-6.45%-29.52%-23.10% 5.64B
-0.27%-2.60%-7.25%-19.83% 4.22B
-1.59%-9.17%+56.51%+67.85% 3.84B
-3.08%-5.58%-24.29%-32.36% 2.65B
Average -0.32%-2.87%+71.86%+56.16% 7.72B
Weighted average by Cap. -0.23%-2.02%+113.31%+137.03%

Financials

2026 *2027 *
Net sales 3.46B 357M 307M 291M 264M 495M 34.09B 498M 1.33B 17.34B 1.34B 1.31B 54.81B 3.71B 383M 330M 312M 283M 531M 36.55B 533M 1.43B 18.6B 1.44B 1.41B 58.76B
Net income 493M 50.83M 43.8M 41.47M 37.59M 70.52M 4.86B 70.87M 189M 2.47B 191M 187M 7.81B 609M 62.83M 54.13M 51.25M 46.46M 87.16M 6B 87.6M 234M 3.05B 236M 231M 9.65B
Net Debt 549M 56.66M 48.82M 46.23M 41.9M 78.61M 5.41B 79.01M 211M 2.75B 213M 208M 8.7B -26.74M -2.76M -2.38M -2.25M -2.04M -3.83M -264M -3.85M -10.28M -134M -10.36M -10.14M -424M
Logo Vitrolife AB
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Employees
1,103
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
89.45SEK
Average target price
129.60SEK
Spread / Average Target
+44.89%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!